A rand, doubleblind, activecontrolled, parallel-grp,singledummy, multicenter,12 wk study to assess the effic.andsafety of symbicort pmdi 2x160/4.5mcg qd compared to symb. pmdi 2x80/4.5mcg qd, symb. pmdi 2x80/4.5mcg bid and to budesonide pmdi 2x160 mcg qd in asthmatic sub's12yrs and over

Trial Profile

A rand, doubleblind, activecontrolled, parallel-grp,singledummy, multicenter,12 wk study to assess the effic.andsafety of symbicort pmdi 2x160/4.5mcg qd compared to symb. pmdi 2x80/4.5mcg qd, symb. pmdi 2x80/4.5mcg bid and to budesonide pmdi 2x160 mcg qd in asthmatic sub's12yrs and over

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2011

At a glance

  • Drugs Budesonide; Budesonide/formoterol
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Jul 2009 Efficacy results were reported in Annals of Allergy, Asthma & Immunology.
    • 18 Apr 2008 New trial record.
    • 18 Mar 2008 Tolerability results presented at AAAAI in 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top